Research Topics
Species | David G S PerahiaSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorderDavid G Perahia
Lilly Research Centre, EMC Building, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK
J Affect Disord 89:207-12. 2005..Discontinuation symptoms are common following antidepressant treatment. This report characterizes symptoms following duloxetine discontinuation...
Duloxetine in the treatment of major depressive disorder: an open-label studyJames I Hudson
McLean Hospital, Belmont, MA, USA
BMC Psychiatry 7:43. 2007..In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined...- Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trialDavid G S Perahia
Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
J Clin Psychiatry 70:706-16. 2009..To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD)... 
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depressionDavid G S Perahia
Lilly Research Centre, EMC Building, Erl Wood Manor, Sunninghill Road, Windlesham GU20 6PH, Surrey, UK
J Psychiatr Res 43:512-8. 2009..In summary, MDD patients who were non- or partial-responders to SSRI treatment were found to have clinically significant pain which improved significantly following switch to duloxetine regardless of the switch method utilized...- Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniquesDavid G S Perahia
Lilly Research Centre, Windlesham, Surrey, UK
J Clin Psychiatry 69:95-105. 2008..To compare 2 methods of switching selective serotonin reuptake inhibitor (SSRI) non-responders or partial responders to duloxetine... - A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depressionDavid G S Perahia
Lilly Research Centre, Windlesham, UK
J Affect Disord 108:33-41. 2008..We hypothesized that combining antidepressant medication with a standardized telephone adherence support intervention would lead to superior outcomes in the treatment of depression compared with antidepressant medication alone... - A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorderDavid G S Perahia
Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
J Psychiatr Res 42:22-34. 2008..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment... - Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled studyDavid G Perahia
Lilly Research Centre, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
Br J Psychiatry 188:346-53. 2006..Relapse rates may be as high as 50% in people with major depressive disorder (MDD) previously treated to remission... - Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristicsDavid G S Perahia
Lilly Research Centre, Windlesham, Surrey, UK
Int Clin Psychopharmacol 21:285-95. 2006..Duloxetine was effective in the treatment of first and subsequent episodes of major depressive disorder, and regardless of duration of the current depressive episode... - Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trialD G S Perahia
Lilly Research Center, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
Eur Psychiatry 21:367-78. 2006..Duloxetine doses of 80 and 120 mg/day were assessed for efficacy and safety in the treatment of major depressive disorder (MDD)... - Duloxetine 60 mg once daily in the treatment of milder major depressive disorderD G S Perahia
Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
Int J Clin Pract 60:613-20. 2006..05). Tolerability was consistent with that seen in previous studies of duloxetine in patients with more severe depression. In conclusion, duloxetine 60 mg/day is effective and well tolerated in milder MDD... - Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDERCatherine Reed
Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK
J Affect Disord 113:296-302. 2009..We studied the impact of antidepressant (AD) treatment on HRQoL outcomes in depressed patients and investigated factors associated with these outcomes in routine practice settings... - Factors influencing depression endpoints research (FINDER): study design and population characteristicsAna Garcia-Cebrian
Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
Eur Psychiatry 23:57-65. 2008..Further investigation into factors associated with HRQoL in depression after treatment initiation is warranted... - Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?David G S Perahia
Lilly Research Centre, Windlesham, Surrey, UK
Int Clin Psychopharmacol 21:311-7. 2006.... - Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trialsBeth A Pangallo
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Curr Med Res Opin 26:2643-51. 2010.... - A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressantCraig Mallinckrodt
Eli Lilly and Company, Indianapolis, IN 46285, USA
Pharm Stat 6:9-22. 2007..Our case study suggests that the DBLE design can provide definitive answers to important questions and may be a useful design for assessing long-term treatment effects... - Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorderNayan Acharya
Eli Lilly Research Center, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:587-94. 2006..Uncertainty regarding relationships of antidepressant treatment and suicidality encouraged systematic review of data on suicidal behaviors and ideation from Phase II and III clinical trials of duloxetine for major depressive disorder (MDD)... - Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) studyMichael Bauer
Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
Eur Psychiatry 23:66-73. 2008..In conclusion, the prescribing of antidepressants varies by country, and the type of antidepressant chosen is influenced by physician- as well as patient-related factors...